ANI Pharmaceuticals (ANIP)

[Just the facts maam]

Is Oppenheimer working for Institutional investors?

The price target of $8 it gave IGI Laboratories, gives it a target market cap of just under $420 million

IG Price Target

The price target of $37 it gave ANI Pharmaceuticals also gives it a target market cap of just under $420 million

Ani Price Target

Ani has been running gross margins in the 75% range (except for the last quarter due to the one time EEMT fee).

IGI has been running gross margins just above the 40% range.

If IGI meets it 2014 earning estimate it will earn $525,000.

ANI will earn in excess of $10 million in the second half of 2014 alone.

In Q2 IGI reported stock holder total equity at just under $8 million (note: ANI completed an offering July 2nd netting $25 million)

In Q2 ANI reported stock holder total equity at over $91.5 million

What is most telling is that ANI netted over$46 million for its offering.

Time for Oppenheimer to look in he mirror. Then again they valued the Bpax/ANI merger at $95 million, so I am not surprised at the fuzzy math.




JMHO